Details of the Drug Reposition

General Information of This Drug (ID: DM4PVDY)

Drug Name
Durvalumab   DM4PVDY
Drug Type
Monoclonal antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Urothelial carcinoma DISRTNTN 2C92.0 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Hepatocellular carcinoma DIS0J828 2C12.02 Phase 3 [2]
------------------------------------------------------------------------------------
4 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 2 [2]
Pancreatic ductal carcinoma DIS26F9Q 2C10.0 Phase 2 [2]
Biliary tract cancer DISBNYQL 2C17 Phase 2 [2]
Melanoma DIS1RRCY 2C30 Phase 2 [2]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Diffuse large B-cell lymphoma DISSACK3 2A81 Phase 1 [2]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)